Original Publication Date: 1 January, 2015
Publication / Source: Future Oncology
Authors: Omar Abdel-Rahman & Mona Fouad
Background: We performed a systematic review and meta-analysis of fatigue, hepatic and metabolic toxicities associated with everolimus intake in patients with solid tumors. Methods: Eligible studies included randomized trials of patients with solid tumors on everolimus describing events of fatigue, hyperlipidemia, hyperglycemia and elevated alanine aminotransferase (ALT).